Improving the Detection, Diagnosis and Treatment of PBA in the Psychiatric Setting – Part 2
This activity is jointly provided by AXIS Medical Education and Novus Medical Education.
This activity is supported by an independent educational grant from Otsuka America Pharmaceutical, Inc.
Scroll to the Bottom of this Information to Begin this Course
Release date: November 4, 2016
Valid through: November 3, 2017
Media: Internet-based Expert Exchange
Estimated Time to Complete Activity: 30 minutes
This activity is intended for psychiatrists and other mental healthcare professionals.
It is estimated that up to 7.1 million people in the United States have pseudobulbar affect (PBA) based on existing disease population estimates; however, the actual prevalence of PBA in the U.S. is unclear. Due to the insidious nature of the onset of PBA and the relative lack of recognition of the initial symptoms, neuropsychiatric practitioners must be aware of PBA, particularly in those patients with significant disease-related risk factors.
Upon completion of this educational activity, participants should be able to:
- Describe the prevalence, burden of illness and underlying neurological conditions/risk factors associated with PBA.
- Utilize objective instruments in assessing patients with neurological conditions to diagnosis PBA.
- Discuss treatment options with their patients who are diagnosed with PBA.
- Physicians — maximum of 0.5 AMA PRA Category 1 Credit™
All other healthcare professionals completing this course will be issued a statement of participation.
Richard S. Isaacson, MD
Associate Professor of Neurology
Weill Cornell Medicine & New York-Presbyterian Hospital
New York, NY
David W. Crumpacker, MD
Assistant Professor of Psychiatry
Texas A&M Health Science Center
Psychiatrist, Private Practice
Physician Continuing Medical Education
In support of improving patient care, this activity has been planned and implemented by AXIS Medical Education and Novus Medical Education. AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AXIS Medical Education designates this activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts of Interest
AXIS requires instructors, planners, managers and other individuals and their spouse/partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Richard Isaacson, MD: Consultant to Accera, Inc.
David W. Crumpacker, MD: Consultant to Avanir, Otsuka, Merck
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/partner have with commercial interests related to the content of this CME activity:
Ronald Viggiani, MD (AXIS): Nothing to disclose.
Steven Scrivner, MPA, CHCP (Novus): Nothing to disclose.
Instructions for Participation and Credit
In order to receive credit, participants must:
- Watch the webcast
- Complete the posttest with a passing score of 70% or higher
- Complete the CME evaluation
There is no fee for this educational activity.
Hardware and Software Requirements
This site is best viewed with an HTML5 compatible browser, this list includes the current versions of Microsoft Internet Explorer, Mozilla Firefox, Google Chrome, and Apple's Safari. You can visit the independent (3rd party) site www.whatismybrowser.com to determine if you have the latest version of your browser. Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. That software may be: Adobe Flash, Apple Quicktime, Adobe Acrobat, Microsoft Powerpoint, Windows Media Player, and Real Networks Real One Player. Where such software is required it will be indicated.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AXIS Medical Education and Novus Medical Education do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This program is part one of a series. Please click the Part 1 button below to go to that activity. To proceed with Part 2, please click the Continue button.